MedTrace Logo

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-01-30

No results posted yet for this study

Summary

Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.

Conditions

  • Hepatitis C Viral Infection
  • Chronic Hepatitis C
  • Hepatitis C (HCV)
  • Hepatitis C Genotype 4

Interventions

DRUG

Faldaprevir

DRUG

TD-6450

DRUG

Ribavirin

Sponsors & Collaborators

  • Trek Therapeutics, PBC

    lead INDUSTRY

Principal Investigators

  • Tarek Hassanein, MD · Southern California Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02593162 on ClinicalTrials.gov